MA55084A - Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau - Google Patents
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peauInfo
- Publication number
- MA55084A MA55084A MA055084A MA55084A MA55084A MA 55084 A MA55084 A MA 55084A MA 055084 A MA055084 A MA 055084A MA 55084 A MA55084 A MA 55084A MA 55084 A MA55084 A MA 55084A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- administration
- treatment
- skin cancer
- cancer
- Prior art date
Links
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 208000000453 Skin Neoplasms Diseases 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 201000000849 skin cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55084A true MA55084A (fr) | 2022-01-05 |
Family
ID=70057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055084A MA55084A (fr) | 2019-02-28 | 2020-02-27 | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (fr) |
| EP (1) | EP3930848A1 (fr) |
| JP (2) | JP2022521800A (fr) |
| KR (1) | KR20210134690A (fr) |
| CN (1) | CN113490529A (fr) |
| AU (1) | AU2020228296B2 (fr) |
| CA (1) | CA3137361A1 (fr) |
| IL (1) | IL285050A (fr) |
| MA (1) | MA55084A (fr) |
| MX (1) | MX2021010228A (fr) |
| SG (1) | SG11202108089SA (fr) |
| WO (1) | WO2020176699A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| US12516382B2 (en) | 2018-12-07 | 2026-01-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring PD-1/PD-L1 signaling pathway members |
| AU2022219955A1 (en) * | 2021-02-11 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| WO2024186917A2 (fr) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions pour l'inhibition de pd-l1 et leurs procédés d'utilisation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7072700A (en) | 1999-08-23 | 2001-03-19 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
| EP1576014B1 (fr) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Anticorps anti pd-1 et leurs utilisations |
| EP2161336B2 (fr) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| AU2008266951C1 (en) | 2007-06-18 | 2025-06-19 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| WO2010027423A2 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| KR20190069615A (ko) | 2008-12-09 | 2019-06-19 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
| WO2013079174A1 (fr) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associées |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| AU2013267267B2 (en) | 2012-05-31 | 2017-10-26 | Genentech, Inc. | Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| CA2956399A1 (fr) | 2014-08-05 | 2016-02-11 | Cb Therapeutics, Inc. | Anticorps anti-pd-l1 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR102833068B1 (ko) * | 2015-12-17 | 2025-07-14 | 노파르티스 아게 | Pd-1에 대한 항체 분자 및 그의 용도 |
| JP7126941B2 (ja) * | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| TWI808938B (zh) | 2016-04-07 | 2023-07-21 | 美商卡默森屈有限公司 | 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷 |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/fr not_active Ceased
- 2020-02-27 AU AU2020228296A patent/AU2020228296B2/en active Active
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko active Pending
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/fr active Pending
- 2020-02-27 CA CA3137361A patent/CA3137361A1/fr active Pending
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
-
2024
- 2024-12-20 JP JP2024225122A patent/JP2025041768A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL285050A (en) | 2021-09-30 |
| CN113490529A (zh) | 2021-10-08 |
| JP2025041768A (ja) | 2025-03-26 |
| AU2020228296A1 (en) | 2021-10-14 |
| AU2020228296B2 (en) | 2025-10-02 |
| WO2020176699A1 (fr) | 2020-09-03 |
| MX2021010228A (es) | 2021-10-26 |
| JP2022521800A (ja) | 2022-04-12 |
| US20220259313A1 (en) | 2022-08-18 |
| KR20210134690A (ko) | 2021-11-10 |
| EP3930848A1 (fr) | 2022-01-05 |
| SG11202108089SA (en) | 2021-08-30 |
| CA3137361A1 (fr) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55084A (fr) | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| EP3641829A4 (fr) | Promédicament d'interféron pour le traitement du cancer | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3664812A4 (fr) | Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative | |
| EP3737376A4 (fr) | Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine | |
| EP3347010A4 (fr) | Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| EP3426254C0 (fr) | Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées | |
| EP3400942A4 (fr) | Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3883567A4 (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| EP4097137A4 (fr) | Combinaisons d'inhibiteurs d'egfr et d'inhibiteurs de ror1 pour le traitement du cancer |